-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, WmKR91cKd5G/TyozKKYqPHfWGMClcOPo1wwOmm4YtJbo99hWPrpZaR5GwoXqMPvi XR9zzhkxwCbcF5a6/4NaRg== 0001193125-08-031242.txt : 20080214 0001193125-08-031242.hdr.sgml : 20080214 20080214152018 ACCESSION NUMBER: 0001193125-08-031242 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080214 DATE AS OF CHANGE: 20080214 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ACCENTIA BIOPHARMACEUTICALS INC CENTRAL INDEX KEY: 0001310094 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-81399 FILM NUMBER: 08614305 BUSINESS ADDRESS: STREET 1: 324 SOUTH HYDE PARK AVE STREET 2: SUITE 350 CITY: TAMPA STATE: FL ZIP: 33606 BUSINESS PHONE: 8138642562 MAIL ADDRESS: STREET 1: 324 SOUTH HYDE PARK AVE STREET 2: SUITE 350 CITY: TAMPA STATE: FL ZIP: 33606 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ODONNELL FRANCIS E JR CENTRAL INDEX KEY: 0001066040 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 709 THE HAMPTONS LANE CITY: TOWN & COUNTRY STATE: MO ZIP: 63017 BUSINESS PHONE: 3145799725 MAIL ADDRESS: STREET 1: 709 THE HAMPTONS LANE CITY: CHESTERFIELD STATE: MO ZIP: 63017 SC 13G 1 dsc13g.htm SCHEDULE 13G Schedule 13G

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED

PURSUANT TO RULES 13d-1 (b), (c), and (d) AND AMENDMENTS

THERETO FILED PURSUANT TO RULE 13d-2 (b)*

 

 

 

 

Accentia Biopharmaceuticals, Inc.

(Name of Issuer)

 

 

Common Stock ($0.001)

(Title of Class of Securities)

 

 

00430L10

(CUSIP Number)

 

 

August 14, 2007

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

 

 

*   The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 00430L10

 

  1  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)

 

            Francis E. O’Donnell, Jr.

    
  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a)  ¨

(b)  ¨

    
  3  

SEC USE ONLY

 

    
  4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

            United States of America

    

 

NUMBER OF  

SHARES  

BENEFICIALLY  

OWNED BY  

EACH  

REPORTING  

PERSON  

WITH  

 

  

  5    SOLE VOTING POWER

 

            5,473,884*

 

  6    SHARED VOTING POWER

 

            0

 

  7    SOLE DISPOSITIVE POWER

 

            5,473,884*

 

  8    SHARED DISPOSITIVE POWER

 

            0

  9  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

            5,473,884*

    
10  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

 

  

¨

 

11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

            12.68%*

    
12  

TYPE OF REPORTING PERSON

 

            IN

    

 

* as of January 31, 2008

Item 1  

(a)

    Name of Issuer:      
     Accentia Biopharmaceuticals, Inc.      
Item 1  

(b)

    Address of Issuer’s Principal Executive Offices:      
    

324 South Hyde Park Avenue, Suite 350

Tampa, Florida 33606

      
Item 2  

(a)

    Name of Persons Filing:      
     Francis E. O’Donnell, Jr., M.D.      
Item 2  

(b)

    Address of Principal Business Office of the Reporting Persons:      
    

709 The Hamptons Lane

Town and Country, MO 63017

      
Item 2  

(c)

    Citizenship:      
     United States of America      
Item 2  

(d)

    Title of Class of Securities:      
     Common Stock      
Item 2  

(e)

    CUSIP Number:      
     00430L10      
Item 3.   If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:   
  (a)    ¨    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
  (b)    ¨    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
  (c)    ¨    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
  (d)    ¨    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
  (e)    ¨    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
  (f)    ¨    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
  (g)    ¨    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
  (h)    ¨    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
  (i)    ¨    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
  (j)    ¨    Group, in accordance with §240.13d-1(b)(1)(ii)(J).
  NOT APPLICABLE. THIS SCHEDULE IS FILED PURSUANT TO 13d-1(d).      

Item 4.    Ownership.      
   (a)    Amount beneficially owned:      
      5,473,884*      
   (b)    Percent of class:      
      12.68%**      
   (c)    Number of shares as to which the person has:      
      (i)    Sole power to vote or to direct the vote:      
         5,473,884*      
      (ii)    Shared power to vote or to direct the vote:      
         0      
      (iii)    Sole power to dispose or to direct the disposition of:      
         5,473,884*      
      (iv)    Shared power to dispose or to direct the disposition of:      
         0      
  

*       4,185,992 shares of common stock held by Hopkins Capital Group, LLC (“HCG”), 412,892 shares of common stock held by The Hopkins Capital Group II, LLC (“Hopkins II”) and 875,000 shares of common stock held by Hopkins Capital Partners, Inc. (“HCP”). Dr. O’Donnell holds voting and investment power over shares held by each of HCG and Hopkins II as its manager and HCP as its officer.

**     as of January 31, 2008.

      
Item 5.    Ownership of Five Percent or Less of a Class.   
   Not Applicable   
Item 6.    Ownership of More than Five Percent on Behalf of Another Person.      
   Not Applicable      
Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
   Not Applicable
Item 8.    Identification and Classification of Members of the Group.      
   Not Applicable      
Item 9.    Notice of Dissolution of Group.      
   Not Applicable      
Item 10.    Certification.      
   After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.      

SIGNATURES

After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 14, 2008

  

/s/ Francis E. O’Donnell, Jr.

  Francis E. O’Donnell, Jr.
 -----END PRIVACY-ENHANCED MESSAGE-----